BD Sees Q3 Sales Hop 10 Percent

The firm also raised its full-year 2011 EPS guidance to a range of $5.65 to $5.70 from an earlier guidance of $5.55 to $5.65.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories